Researchers Identify Multi-Action Drug Candidate For Type 2 Diabetes And Bone Disease Posted on: July 28, 2016 in News | Life Science News | Pharma News By: Sarah Massey, M.Sc. Share this: Click to share on LinkedIn (Opens in new window) LinkedIn Click to share on Facebook (Opens in new window) Facebook Click to share on X (Opens in new window) X Click to share on Reddit (Opens in new window) Reddit Click to email a link to a friend (Opens in new window) Email Subscribe Related Vitals Sanofi’s Wayrilz (Rilzabrutinib) Wins FDA Approval as First BTK Inhibitor for ITP News September 12, 2025 Novo Nordisk Layoffs to Hit 11% of Workforce in $1.25B Savings Plan News September 10, 2025 5 Reasons to Attend the Upcoming 9th Operational Excellence in Clinical Trials Summit News September 5, 2025 Inside the Curanex Pharmaceuticals IPO: Botanical Therapies for Ulcerative Colitis and More News September 4, 2025 Nasus Pharma IPO Raises $10M to Advance Needle-Free Epinephrine Business & Finance News September 2, 2025 Related Webinars October 29, 2025 Redefining Clinical Success for Sites Through Patient-Centered Support October 22, 2025 Overcoming Regulatory Hurdles in AAV Production October 29, 2025 Smarter Site Feasibility Strategies for Predictable Enrollment in Late-Stage Oncology Trials October 27, 2025 Simplifying CRISPR Therapeutic Manufacturing: Practical Solutions to Accelerate and Simplify Manufacturing October 27, 2025 Can Neuroimaging Save Psychedelic Drug Development? Join or login to leave a comment JOIN LOGIN Subscribe to our newsletters Not a member yet? Sign up for our newsletters and receive webinars, vitals, and updates for your topic of choice Preferences Xtalks Vitals Vitals Life Science Vitals Food Industry Vitals Medical Devices Marketing Insights Blog First Name*Last Name*Country*Email* CAPTCHA
Join or login to leave a comment
JOIN LOGIN